Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...
Vertex Pharmaceuticals reports Q4 EPS $3.98, consensus $4.02
Reports Q4 revenue $2.91B, consensus $2.78B. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another ...
Vertex Pharmaceuticals sees FY25 revenue $11.75B-$12.0B, consensus $11.85B
Vertex Pharmaceuticals sees FY25 revenue $11.75B-$12.0B, consensus $11.85B Sees FY25 R&D, AIPR&D and SG&A expenses of $4.9B-$5.0B.
The Motley Fool8d
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...
Seeking Alpha8d
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential ...
Morningstar8d
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Yahoo Finance7d
Vertex, Inc. (VERX)
Not to be confused with Vertex Pharmaceuticals, Vertex is a company specializing in consulting services and tax preparation software. S&P 500 components Fortinet and Boston Scientific are among ...